Outcalt Samantha D, Hoen Helena Maria, Yu Zhangsheng, Franks Tenesha Marie, Krebs Erin E
Center for Health Information and Communication, Department of Veterans Affairs (VA) Health Services Research & Development Service, Indianapolis, IN; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN; and Regenstrief Institute Inc, Indianapolis, IN;
J Rehabil Res Dev. 2016;53(1):37-44. doi: 10.1682/JRRD.2014.10.0237.
Because posttraumatic stress disorder (PTSD) is both prevalent and underrecognized, routine primary care-based screening for PTSD has been implemented across the Veterans Health Administration. PTSD is frequently complicated by the presence of comorbid chronic pain, and patients with both conditions have increased symptom severity and poorer prognosis. Our objective was to determine whether the presence of pain affects diagnosis and treatment of PTSD among Department of Veterans Affairs (VA) patients who have a positive PTSD screening test. This retrospective cohort study used clinical and administrative data from six Midwestern VA medical centers. We identified 4,244 VA primary care patients with a positive PTSD screen and compared outcomes for those with and without a coexisting pain diagnosis. Outcomes were three clinically appropriate responses to positive PTSD screening: (1) mental health visit, (2) PTSD diagnosis, and (3) new selective serotonin reuptake inhibitor (SSRI) prescription. We found that patients with coexisting pain had a lower rate of mental health visits than those without pain (hazard ratio: 0.889, 95% confidence interval: 0.821-0.962). There were no significant differences in the rate of PTSD diagnosis or new SSRI prescription between patients with and without coexisting pain.
由于创伤后应激障碍(PTSD)既普遍又未得到充分认识,退伍军人健康管理局已在所有机构实施基于初级保健的PTSD常规筛查。PTSD常因合并慢性疼痛而复杂化,同时患有这两种疾病的患者症状严重程度增加且预后较差。我们的目的是确定疼痛的存在是否会影响退伍军人事务部(VA)中PTSD筛查呈阳性的患者的PTSD诊断和治疗。这项回顾性队列研究使用了来自六个中西部VA医疗中心的临床和管理数据。我们确定了4244名VA初级保健患者,其PTSD筛查呈阳性,并比较了有和没有并存疼痛诊断的患者的结果。结果是对PTSD阳性筛查的三种临床适当反应:(1)心理健康就诊,(2)PTSD诊断,以及(3)新的选择性5-羟色胺再摄取抑制剂(SSRI)处方。我们发现,并存疼痛的患者心理健康就诊率低于无疼痛的患者(风险比:0.889,95%置信区间:0.821-0.962)。有无并存疼痛的患者在PTSD诊断率或新的SSRI处方率方面没有显著差异。